INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Conn Avi Daniel reported TVRD

Chief Financial Officer · Tvardi Therapeutics, Inc. · Tvardi Therapeutics, Inc. — Employee Stock Option (right to buy)

Side
A
Value
—
Shares
17.5K
Price
—
Executed
Dec 16, 2025
Disclosed
Dec 18, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Dec 16 executedDec 18, 2025 disclosed

TVRD · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TVRD

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    SD
    Shiff Susan Ph.D.Director
    TVRDTvardi Therapeutics, Inc.
    Grant or award
    		A—
    6,000 sh
    		Jun 9, 2026Jun 11, 2026
    traded Jun 9, 2026
    		+2dSEC FORM 4

    Evidence

    9
    OP
    O'Brien Stephen PaulPrincipal Accounting Officer
    TVRDTvardi Therapeutics, Inc.
    Grant or award
    		A—
    15.0K sh
    		Jan 29, 2026Feb 2, 2026
    traded Jan 29, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AN
    Alibhai Imran NizamudinDirector, Chief Executive Officer
    TVRDTvardi Therapeutics, Inc.
    Grant or award
    		A—
    115.0K sh
    		Jan 29, 2026Feb 2, 2026
    traded Jan 29, 2026
    		+4dSEC FORM 4

    Evidence

    9
    KD
    Kauh John Saewook M.D.Chief Medical Officer
    TVRDTvardi Therapeutics, Inc.
    Grant or award
    		A—
    45.0K sh
    		Jan 29, 2026Feb 2, 2026
    traded Jan 29, 2026
    		+4dSEC FORM 4

    Evidence

    9
    CD
    Conn Avi DanielChief Financial Officer
    TVRDTvardi Therapeutics, Inc.
    Grant or award
    		A—
    45.0K sh
    		Jan 29, 2026Feb 2, 2026
    traded Jan 29, 2026
    		+4dSEC FORM 4

    Evidence

    9
    OP
    O'Brien Stephen PaulPrincipal Accounting Officer
    TVRDTvardi Therapeutics, Inc.
    Grant or award
    		A—
    4,000 sh
    		Dec 16, 2025Dec 18, 2025
    traded Dec 16, 2025
    		+2dSEC FORM 4

    Evidence

    9
    AN
    Alibhai Imran NizamudinDirector, Chief Executive Officer
    TVRDTvardi Therapeutics, Inc.
    Grant or award
    		A—
    47.5K sh
    		Dec 16, 2025Dec 18, 2025
    traded Dec 16, 2025
    		+2dSEC FORM 4

    Evidence

    9
    KD
    Kauh John Saewook M.D.Chief Medical Officer
    TVRDTvardi Therapeutics, Inc.
    Grant or award
    		A—
    17.5K sh
    		Dec 16, 2025Dec 18, 2025
    traded Dec 16, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002064982-25-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 16, 2025
    Published
    Dec 18, 2025
    Ingested by INSIDER
    Nov 5, 04:26 UTC
    Last re-read
    Nov 5, 04:26 UTC

    Extracted facts

    Filer
    Conn Avi Daniel
    Role
    Chief Financial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Tvardi Therapeutics, Inc. — Employee Stock Option (right to buy)
    Ticker
    TVRD
    Shares
    17.5K
    Price per share
    $0
    Execution date (reported)
    Dec 16, 2025
    Owned after transaction
    17.5K shares
    Days from execution to publication
    2

    What this establishes

    Conn Avi Daniel filed this Form 4 reporting a grant or award of TVRD on Dec 16, 2025. It became public on Dec 18, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Conn Avi Danielcik:0002064982
    Issuer
    Tvardi Therapeutics, Inc.cik:0001346830

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.